Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
38% minder consulten door ondersteuning met app bij RA
aug 2022 | RA
jan 2022 | Osteoporose
dec 2021 | Osteoporose
sep 2021 | Osteoporose
sep 2021 | Osteoporose
aug 2021 | Osteoporose
jul 2021 | Eczeem, Huidinfecties, Psoriasis
dec 2020 | Osteoporose
dec 2020 | Osteoporose
nov 2020